Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Registration Number
- NCT04681118
- Locations
- 🇺🇸
University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States
🇺🇸UMass Medical School, Worcester, Massachusetts, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS
- Conditions
- Multiple Sclerosis, Chronic Progressive
- Interventions
- Biological: NurOwn (MSC-NTF cells)
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT03799718
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The Mount Sinai Hospital, New York, New York, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Biological: NurOwn® (MSC-NTF cells)Other: PlaceboOther: Bone Marrow aspiration
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT03280056
- Locations
- 🇺🇸
University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Biological: PlaceboBiological: Nurown MSC-NTF cells
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT02017912
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UMass Medical School, Worcester, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT01777646
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: MSC-NTF cells transplantation (IM)Biological: MSC-NTF cells transplantation (IT)
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Brainstorm-Cell Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01051882
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel